Targeting HLA-h or HLA-j specific peptides for treating triple negative breast cancer

By targeting HLA-H and HLA-J peptides specific to TNBC cells, the immunotherapy addresses the challenge of ineffective cancer cell targeting, enhancing treatment efficacy and reducing toxicity.

WO2026058015A1PCT designated stage Publication Date: 2026-03-19INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/000501
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2026-03-19

AI Technical Summary

Technical Problem

Current immunotherapies for triple negative breast cancer (TNBC) face challenges due to the lack of specific tumor surface markers, leading to ineffective targeting of cancer cells and increased toxicity, as conventional CAR-based therapies struggle to differentiate between cancer and healthy cells.

Method used

Identification and targeting of specific peptides from HLA-H and HLA-J proteins expressed on the surface of TNBC cells, which are not present in healthy epithelial cells, using immunotherapeutic molecules such as CAR-expressing macrophages and antibodies to enhance treatment efficacy and reduce side effects.

Benefits of technology

The targeted peptides enable precise immunotherapy by focusing immune cells on TNBC cells, potentially increasing treatment effectiveness while minimizing harm to healthy tissues.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present results show for the first time that the HLA proteins HLA-H and HLA-J are specifically expressed at the surface of breast tumor cells (in particular Triple Negative Breast Cancer) and can therefore serve as specific targets for various immunotherapeutic agents, preferably CAR-expressing macrophages. The present invention therefore provides new immunotherapeutic molecules recognizing peptides that are specifically present in the HLA protein HLA-H or in the HLA protein HLA-J at the surface of breast cancer cells, nucleic acids encoding said molecules, immune cells expressing said molecules, as well as therapeutical uses and / or treatment methods involving them, for alleviating the symptoms of patients suffering from breast cancer, in particular from Triple Negative Breast Cancer. The invention specifically proposes to use furin-inhibited CAR-macrophages targeting extracellular peptides of the HLA-H or HLA-J proteins for treating patients suffering from breast cancer, in particular from Triple Negative Breast Cancer.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • HLA-j and medical / diagnostic uses thereof

    WO2019207039A1

  • HLA-h in medicine and diagnostics

    WO2021005001A1

  • Battery and electric device

    WO2024000093A1

  • Methods for diagnosing the effectiveness of Anti-tumor treatment

    WO2021005002A1

  • HLA-h, HLA-j, HLA-l, HLA-v and HLA-y as therapeutic and diagnostic targets

    WO2021078679A1